Definitive Contract 75N93023C00043
Award Date
9/30/23
Potential Completion Date
9/29/28
Potential Value
$4.5M
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
State Of California Controllers Office
NAICS Category
541512 - Computer Systems Design Services
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
La Jolla, CA 92093, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
24
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $10,517,896.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of California, San Diego (UCSD). The award is part of NIAID's Vaccine Adjuvant Discovery Program (VADP), which supports the identification and characterization of novel, effective, and safe vaccine adjuvants. The contract does not have a set-aside designation. UCSD will lead the research efforts, which will focus on four key areas: (1)...
The University of California, San Diego (UCSD) was awarded a $10,223,791 Definitive Federal Contract by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. This contract does not have a set-aside designation. As part of this effort, UCSD has issued subcontracts to several companies, including Life Technologies Corporation, Inimmune Corp,...
The University of California, San Diego was awarded a definitive cost-no-fee contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases totaling $12.7 million to support the Adjuvant Discovery Program. The prime contractor, UC San Diego, will work with several notable subcontractors including Inimmune Corp, Miltenyi Biotec, Repertoire Genesis, Life Technologies Corporation, Icahn School of Medicine at Mount Sinai, and Agilent Technologies over the...
This federal contract award, valued at $8,762,844.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (DHHS). The contract was awarded to the University of California, Irvine (UC Irvine) to conduct a research program comparing multiple vaccine adjuvants across various platforms. The goal is to establish immunological profiles of the adjuvants' strength,...
This is a $8,012,241.00 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to the University of California San Diego. The contract is for biomedical research and analysis services and does not have a set-aside designation. University of California San Diego has previously provided similar medical laboratory testing, brain analysis, and other services to the Department of Veterans Affairs...
This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
This federal contract award, valued at $5,822,726.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Duke University. The contract is for the "ADJUVANT COMPARISON AND CHARACTERIZATION" project, which aims to compare multiple vaccine adjuvants using various vaccine and antigen platforms through comprehensive immune assessments. The contract does not have a set-aside designation. This contract is part of a broader NIAID program that seeks to...
This federal contract award is for the development of an adjuvant for a thermostable respiratory influenza vaccine. The contract, valued at $599,749.00, was awarded to Universal Stabilization Technologies, Inc. by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases under the Small Business Innovation Research (SBIR) Program Phase I. The contract is a Definitive Contract with a Firm Fixed Price pricing type, and the...
This is a $5,656,759.38 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the University of Chicago for the development of influenza vaccines using an immuno-modulator adjuvant and multi-platform approach. The contract has an ultimate completion date of September 29, 2028. It is not a set-aside contract. The University of Chicago is a renowned private research university that has substantial expertise in federal contract...
This is a $9,983,467.70 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Chicago to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. The contract has a period of performance through April 30, 2026 and was originally solicited through a Broad Agency Announcement issued by NIAID in 2018. The University of Chicago is collaborating with the IIT Research Institute and the University of...